BioCentury
ARTICLE | Company News

EC approves Takeda's Entyvio for UC, Crohn's

May 28, 2014 1:23 AM UTC

The European Commission approved Entyvio vedolizumab from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to treat moderate to severe active ulcerative colitis (UC) and Crohn's disease (CD) in patients who had an inadequate response to or were intolerant to either conventional therapy or a tumor necrosis factor (TNF) alpha antagonist therapy. Earlier this month, FDA approved the humanized mAb against integrin alpha(4)beta(7) for the indications. ...